Search results
Found 18172 matches for
The US Food and Drug Administration (FDA) has recently licensed a form of ketamine – esketamine – as a treatment for depression which is resistant to other treatments. It is administered as a nasal spray in a clinic, initially twice a week, then weekly or fortnightly. Regular doses of the drug are necessary to prevent relapse.
Athena Swan renewal application form March 2024
Athena Swan renewal application form
Athena Swan renewal application form_v1-3_DoPsych_July2024_ AP v8 redacted clean.docx (2 MB)
Future Action Plan - Psychiatry July 2024
Athena Swan Future Action Plan July 2024